Bile duct cancer is a form of cancer in which epithelial cells are mutated which shows epithelial differentiation in the bile duct. It is type of rare disease.
Furthermore, major key players are focusing on adoption of inorganic strategies such as collaborations, in order to strengthen their product offerings and presence in the global bile duct cancer market
In Mach 2021, QED Therapeutics a biotechnology company, announced that it collaborated with Helsinn Group, a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care, rare disease products, and a broad development pipeline. The collaboration is to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer).
The global bile duct cancer market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period (2021-2028).
Figure 1. Global Bile Duct Cancer Market Share (%) in Terms of Value, By Region, 2021
Rising research and development activities by pharmaceutical companies is expected to aid in the growth of the global bile duct cancer market
For instance, in 2015, Leap therapeutics, developed a humanized monoclonal antibody DKN-01 which is under clinical trial phase I for treatment of bile duct cancer through its anti-neoplastic activity.
Furthermore, in September 2019, Merck Sharp & Dohme Corp, a pharmaceutical company, initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment of cholangiocarcinoma (bile duct cancer). The study is currently in Phase 3 clinical trials and is expected to be completed by August 2023.
|Base Year:||2020||Market Size in 2021:||US$ 185.4 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||12.8%||2028 Value Projection:||US$ 429.6 Mn|
Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P. and Delcath Systems, Inc.
|Restraints & Challenges:||
Figure 2. Global Bile Duct Cancer Market Share (%), by Distribution Channel, 2021
Global Bile Duct Cancer Market– Impact of Coronavirus (COVID-19) Pandemic- Government Initiatives to Combat COVID-19
COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets
Furthermore, in May 2020, the Government of India announced relief for an amount of US$ 13.3 per person for daily wagers and construction workers for all states and union territories
In June 2020, All of Us Research Program, part of the National Institutes of Health, announced COVID-19 research initiatives through antibody testing. The study collaborators include the Frederick National Laboratory for Cancer Research, supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases along with the Centers for Disease Control and Prevention.
Hence, increasing research and development of drugs is expected to drive the cholangiocarcinoma market growth.
Global Bile Duct Cancer Market Restraint
Expensive treatments of bile duct cancer on a global level is expected to hamper the market growth over the forecast period.
According to the data published in UCL School of Pharmacy report 2020, oncology treatment (including chemotherapy, targeted therapy, and others) related costs in the U.K. are approximately 0.1 to 0.15% of GDP or accounts 20 to 25% for oncology treatments.
High cost associated with the treatment of cholangiocarcinoma patients is expected to hamper the market growth. According to the U.S. National Library of Medicine report 2017, the total cost of treatment for cholangiocarcinoma in year 1997 was US$ 36,460 and US$ 77,753 in 2012.
Major players operating in the global bile duct cancer market include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile ducts. The symptoms of bile duct cancer may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever.
Increasing prevalence of bile duct cancer has driven the market growth, For instance, according to American Cancer Society report 2018, each year around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.
Key players are focusing on product approvals to strengthen their position in the global bile duct cancer market. In February 2021, Eisai Co., Ltd., a pharmaceutical company, received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its Fibroblast Growth Factor (FGF) receptor selective tyrosine kinase inhibitor E7090.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.